OCEANSIDE, CA--(Marketwired - Oct 6, 2015) - Therapeutics Solutions International, Inc. (
Dr. Kesari was previously Professor of Neurosciences at UC San Diego School of Medicine, and Director of Neuro-Oncology at Moores UCSD Cancer Center. His research investigates the biology of gliomas with the aim of developing new therapeutics for patients with brain tumors. Dr. Kesari is currently Professor of Neurosciences and Chair of the Department of Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute at Providence St. John's Health Center in Santa Monica, CA.
"We are very honored today with the appointment of Dr. Kesari to our Scientific Advisory Board. Dr. Kesari specializes in the diagnosis and treatment of primary and metastatic brain tumors and related disorders in cancer patients. Dr. Kesari has a laboratory interest in targeted molecular therapeutics, biomarker discovery, cancer stem cell biology, hydrocephalus, neurotoxicity, and translating these laboratory discoveries into novel, personalized clinical trials in cancer patients," said Timothy Dixon, President and CEO of Therapeutic Solutions International.
"I am honored to be appointed to the Scientific Advisory Board and look forward to working with the Board to help advance new approaches for unmet needs within Neuro-Oncology and Neurotherapeutics," commented Dr. Kesari.
As was previously announced on July 9, 2015, Therapeutic Solutions filed on July 8, 2015 with the United States Patent and Trademark Office (the "USPTO"), the accepted U.S. Application No. 62/190170 titled, "Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions," to which Dr. Kesari was a co-inventor on this Patent filing.
Dr. Kesari received a B.A., Biology and Mathematics 1992 from University of Pennsylvania, College of Arts and Sciences, University of Pennsylvania, School of Medicine and in 1996 he received a Ph.D. in Molecular Biology at the University of Pennsylvania, School of Medicine, and his M.D. in 1999 from the University of Pennsylvania, School of Medicine.
About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Contact Information:
CONTACT INFORMATION
Therapeutic Solutions International, Inc.
ir@tsoimail.com